Unilife has developed a wearable infusion device for self-administration of an emerging class of drugs that require large volume doses.
Noting a number of drugs requiring large doses in development pipelines, Unilife has developed an infusion system with volumes up to 10ml. By offering large volumes and features such as ergonomic design Unilife believes it can occupy what it sees as an emerging clinical trial drug delivery niche.
“The conventional patch pumps that have been developed for the delivery of drugs such as insulin are largely unsuitable for delivery of these [large volume] drugs”, Alan Shortall, CEO of Unilife, said.
Unilife has designed the device to deliver macro-molecules with complex protein formulations and high viscosities. Large doses of these drugs, used in acute, palliative and chronic diseases, are needed, Unilife said, and as such they require specialist delivery technology.
The device stores the drug, at volumes ranging from 3ml to 10ml, and attaches to the delivery site. Infusion begins when a button is pressed and the delivery period, spanning minutes or hours, is set by the pharmaceutical company.
Companies can also choose when the device is filled. “For clinical trial purposes, the AutoInfusor can either be filled at the time of use for the convenience of pharmaceutical customers, or supplied in a prefilled format”, Shortall said.
While wearing the device patients can continue their normal routine before removing and disposing of the device when delivery is completed. Patients are alerted when administration is over by ‘a series of audible, tactile and visual indicators’.